Avenacy has filed a notice of an exempt offering of securities to raise $34,030,368.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Avenacy is raising up to $34,030,368.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Avenacy
Avenacy is a rapidly growing U.S.-based specialty pharmaceutical company focused on providing critical injectable medications used to treat patients in various medically supervised settings, from acute care hospitals to outpatient clinics and physician offices. Through a rigorous and optimized selection process, the Company is building out a pipeline of high-quality FDA approved injectable products to ensure a resilient portfolio that can meet the needs of todays dynamic drug supply chain. With an experienced team, commitment to quality and reliability, and product offerings intended to facilitate safe and efficient patient care, Avenacy strives to be a trusted partner for essential injectable medications.
To learn more about Avenacy, visit http://avenacy.com/
Avenacy Linkedin Page: https://www.linkedin.com/company/avenacy/
Contact:
Jeffrey Yordon, Chief Executive Officer
877-283-6229
https://www.linkedin.com/in/jeffrey-yordon-15376bb7/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.